{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:38:35Z","timestamp":1777505915955,"version":"3.51.4"},"reference-count":123,"publisher":"Elsevier","isbn-type":[{"value":"9780702040870","type":"print"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1016\/b978-0-7020-4087-0.00054-1","type":"book-chapter","created":{"date-parts":[[2013,12,21]],"date-time":"2013-12-21T03:15:22Z","timestamp":1387595722000},"page":"809-824","source":"Crossref","is-referenced-by-count":14,"title":["Commonly used endocrine drugs"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0005","first-page":"126","article-title":"AACE Position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. American Association of Clinical Endocrinologists","volume":"11","author":"AACE","year":"2005","journal-title":"Endocr Pract"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(96)06032-1","article-title":"Insulin analogues","volume":"349","author":"Barnett","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0025","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.3748\/wjg.v12.i38.6232","article-title":"Propylthiouracyl-induced severe liver toxicity: an indication for alanine aminotransferase monitoring?","volume":"12","author":"Benyounes","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0140-6736(92)92431-E","article-title":"\u201cFriendly fire\u201d in medicine: hormones, homografts and Creutzfeldt\u2013Jakob disease","volume":"340","author":"Brown","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0035","first-page":"745","article-title":"Insulin neuritis: a case report","volume":"59","author":"Caravati","year":"1933","journal-title":"Va Med Monthly"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0040","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1210\/jc.2006-1610","article-title":"Long-term treatment with recombinant insulin-like growth factor (IGF-I) in children with severe IGF-I deficiency due to growth hormone insensitivity","volume":"92","author":"Chernausek","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/(SICI)1096-8628(19990305)83:1<43::AID-AJMG8>3.0.CO;2-C","article-title":"Methimazole embryopathy: delineation of the phenotype","volume":"83","author":"Clementi","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/jc.2007-1534","article-title":"The role of recombinant human insulin-like growth factor-I in treating children with short stature","volume":"93","author":"Collett-Solberg","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(60)90335-4","article-title":"A comparison of potassium perchlorate, methylthiouracil, and carbimazole in the treatment of thyrotoxicosis","volume":"1","author":"Crooks","year":"1960","journal-title":"Lancet"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0060","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0149-2918(01)80110-7","article-title":"Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus","volume":"23","author":"Dailey","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0065","first-page":"227","article-title":"Giant invasive prolactinoma: a case report and review of nine further cases","volume":"74","author":"Davis","year":"1990","journal-title":"Q J Med"},{"issue":"Suppl 3","key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0070","first-page":"2","article-title":"Consensus statement of the Movement Disorder Society on Tremor","volume":"13","author":"Deuschl","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mds.870110113","article-title":"Quantification of essential tremor in writing and drawing","volume":"11","author":"Elble","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0080","unstructured":"EMA aspart insulin product information (2012). European Medicines Agency (EMA), viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000258\/WC500030372.pdf"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0085","unstructured":"EMA detemir insulin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000528\/WC500036662.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0090","unstructured":"EMA exenatide product information (2012). EMA, viewed 30OCT2012: www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000698\/WC500051845.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0095","unstructured":"EMA glargine insulin product information (2010). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000284\/WC500036082.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0100","unstructured":"EMA glimepiride opinion following referral (1998). EMA, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Amaryl_29\/WC500011177.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0105","unstructured":"EMA glulisine insulin product information (2011). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000557\/WC500025250.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0110","unstructured":"EMA lispro insulin product information (2011). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000088\/WC500050332.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0115","unstructured":"EMA long-acting human insulin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000441\/WC500033307.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0120","unstructured":"EMA liraglutide product information (2012). EMA, viewed 30OCT2012: http: \/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001026\/WC500050017.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0125","unstructured":"EMA mecasermin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000704\/WC500032225.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0130","unstructured":"EMA metformin-pioglitazone product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000655\/WC500032620.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0135","unstructured":"EMA metformin-sitagliptin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000861\/WC500038805.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0140","unstructured":"EMA metformin-vildagliptin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000807\/WC500030594.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0145","unstructured":"EMA nateglinide product information (2011). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000335\/WC500057862.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0150","unstructured":"EMA NPH insulin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000442\/WC500044920.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0155","unstructured":"EMA parathyroid hormone product information (2012). EMA, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000659\/WC500041343.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0160","unstructured":"EMA pegvisomant product information (2012). EMA, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000409\/WC500054629.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0165","unstructured":"EMA pioglitazone product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000285\/WC500021386.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0170","unstructured":"EMA propylthiouracil risk (2009). EMA - Pharmacovigilance Working Party, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Report\/2009\/12\/WC500016972.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0175","unstructured":"EMA recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer (2011). Viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2011\/07\/WC500109176.pdf"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0180","unstructured":"EMA recommends suspension of Avandia, Avandamet and Avaglim (2010). Viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/09\/WC500096996.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0185","unstructured":"EMA regular human insulin and fixed combinations regular and NPH product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000761\/WC500033441.pdf"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0190","unstructured":"EMA regular human insulin and fixed combinations regular and NPH product information (2011). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000201\/WC500033784.pdf"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0195","unstructured":"EMA repaglinide product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000362\/WC500041220.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0200","unstructured":"EMA saxagliptin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001039\/WC500044316.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0205","unstructured":"EMA sitagliptin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000722\/WC500039054.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0210","unstructured":"EMA somatropin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000607\/WC500043695.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0215","unstructured":"EMA somatropin product information (2011). EMA, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000315\/WC500040084.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0220","unstructured":"EMA teriparatide product information (2012). EMA, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000425\/WC500027994.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0225","unstructured":"EMA tolvaptan product information (2012). EMA, viewed 30OCT2012: http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000980\/WC500048716.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0230","unstructured":"EMA ultralente insulin product information (2008). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000439\/WC500058877.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0235","unstructured":"EMA vildagliptin product information (2012). EMA, viewed 30OCT2012: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001048\/WC500038241.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0240","unstructured":"eMC acarbose product information (2012). The electronic Medicines Compendium (eMC) UK, viewed 30OCT2012: http:\/\/www.medicines.org.uk\/guides\/download\/acarbose\/Diabetes\/acarbose%20100mg%20tablets."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0245","unstructured":"eMC carbimazole discontinued product information (2012). eMC UK, viewed 30OCT2012: http:\/\/www.medicines.org.uk\/emc\/medicine\/14594."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0250","unstructured":"eMC gliclazide product information (2012). eMC UK, viewed 30OCT2012: http:\/\/www.medicines.org.uk\/EMC\/medicine\/1942\/SPC\/Diamicron\/."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0255","unstructured":"eMC glimepiride product information (2012). eMC UK, viewed 30OCT2012: http:\/\/www.medicines.org.uk\/EMC\/medicine\/27034\/SPC\/Amaryl+1mg+Tablets\/."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0260","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2337\/diacare.19.11.1185","article-title":"Metformin\u2019s effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas","volume":"19","author":"Fangh\u00e4nel","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0265","unstructured":"FDA acarbose label (2012). Food and Drug Administration (FDA), viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020482s025lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0270","unstructured":"FDA aspart insulin label (2009). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/019938s064,019959s067,019991s068,020986s055lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0275","unstructured":"FDA bromocriptine label (2011). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020866s002lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0280","unstructured":"FDA bromocriptine label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/017962s065s068lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0285","unstructured":"FDA cabergoline label (2011). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020664s012lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0290","unstructured":"FDA conivaptan label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021697s003lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0295","unstructured":"FDA desmopressin label (2003). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/21333slr001_Minirin_lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0300","unstructured":"FDA desmopressin label (2007). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/017922s038,018938s027,019955s013lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0305","unstructured":"FDA detemir insulin label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021536s041lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0310","unstructured":"FDA exenatide label (2011). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021773s029s030lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0315","unstructured":"FDA glargine insulin label (2009). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021081s034lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0320","unstructured":"FDA glimepiride label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020496s022lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0325","unstructured":"FDA glulisine insulin label (2009). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021629s008lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0330","unstructured":"FDA glyburide also known as glibenclamide label (2009). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/017532s030lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0335","unstructured":"FDA lanreotide label (2011). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022074s003lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0340","unstructured":"FDA leuprolide pediatrics label (2012). FDA, 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019943s031,020011s038,020708s031lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0345","unstructured":"FDA leuprolide adults label (2011). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019010s035lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0350","unstructured":"FDA levothyroxine label (2009). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021292s002lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0355","unstructured":"FDA liothyronine label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/10379s47lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0360","unstructured":"FDA lispro insulin label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020563s123lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0365","unstructured":"FDA mecasermin label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021839s010lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0370","unstructured":"FDA metformin label (2008). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020357s031,021202s016lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0375","unstructured":"FDA metformin-pioglitazone label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021842s008s010lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0380","unstructured":"FDA metformin-sitagliptin label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022044s026lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0385","unstructured":"FDA methimazole label (2001). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2001\/007517s022lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0390","unstructured":"FDA miglitol label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020682s010lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0395","unstructured":"FDA nateglinide label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021204s014lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0400","unstructured":"FDA NPH insulin label (2010). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/018781s114lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0405","unstructured":"FDA octreotide label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019667s061lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb9000","unstructured":"FDA pasireotide label (2012). FDA viewed 15OCT2013: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/200677lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0410","unstructured":"FDA pegvisomant label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021106s031lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0415","unstructured":"FDA pioglitazone label (2011). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021073s043s044lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0420","unstructured":"FDA pramlintide label (2007). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021332s006lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0425","unstructured":"FDA propylthiouracil Drug Safety Communication (2009). FDA, viewed 30OCT2012: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm209023.htm."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0430","unstructured":"FDA propylthiouracil Information for Healthcare Professionals (2009). FDA, viewed 30OCT2012: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm162701.htm"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0435","unstructured":"FDA regular and NPH human insulin fixed combination label (2010). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019717s094lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0440","unstructured":"FDA repaglinide label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020741s040lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0445","unstructured":"FDA saxagliptin label (2011). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022350s004lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0450","unstructured":"FDA sitagliptin label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021995s025lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0455","unstructured":"FDA somatropin label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020280s072lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0460","unstructured":"FDA teriparatide label (2009). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021318s012lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0465","unstructured":"FDA tolvaptan label (2012). FDA, viewed 30OCT2012: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022275s005lbl.pdf."},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0470","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1085\/jgp.16.5.741","article-title":"An attempt at peptic synthesis of insulin","volume":"16","author":"Fisher","year":"1933","journal-title":"J Gen Physiol"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0475","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1042\/bj0291055","article-title":"Zinc content of bovine pancreas","volume":"29","author":"Fisher","year":"1935","journal-title":"Biochem J"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0480","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/01.STR.28.3.584","article-title":"Specific changes in human brain after hypoglycemic injury","volume":"28","author":"Fujioka","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0485","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1055\/s-0030-1253420","article-title":"Medical treatment of hyperthyroidism: state of the art","volume":"118","author":"Fumarola","year":"2010","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0490","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ana.21952","article-title":"Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy","volume":"67","author":"Gibbons","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0495","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1001\/jama.284.18.2322","article-title":"Creutzfeldt\u2013Jakob disease in the United States: 1979\u20131998","volume":"284","author":"Gibbons","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0500","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2337\/diacare.16.10.1387","article-title":"Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women","volume":"16","author":"Giugliano","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0505","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0510","first-page":"681","article-title":"Effect on compliance, acceptability of blood glucose self-monitoring and HbA(1c) of a self-monitoring system developed according to patient\u2019s wishes. The ACCORD study","volume":"27","author":"Halimi","year":"2001","journal-title":"Diabetes Metab"},{"issue":"Suppl 1","key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0515","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.diabres.2003.12.012","article-title":"Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide","volume":"66","author":"Hamaguchi","year":"2004","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0520","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00002018-200022040-00004","article-title":"Comparative tolerability of sulphonylureas in diabetes mellitus","volume":"22","author":"Harrower","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0525","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/cc7100","article-title":"Clinical review: critical illness polyneuropathy and myopathy","volume":"12","author":"Hermans","year":"2008","journal-title":"Crit Care"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0530","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1001\/jama.2008.815","article-title":"Tight glucose control in critically ill adults","volume":"300","author":"Hermans","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006832.pub2","article-title":"Interventions for preventing critical illness polyneuropathy and critical illness myopathy","volume":"1","author":"Hermans","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0540","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0015-0282(16)60489-2","article-title":"Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia","volume":"51","author":"Kletzky","year":"1989","journal-title":"Fertil Steril"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0545","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2265.2000.00901.x","article-title":"CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas","volume":"52","author":"Leong","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0550","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ageing\/afj042","article-title":"Metformin-related vitamin B12 deficiency","volume":"35","author":"Liu","year":"2006","journal-title":"Age Ageing"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0555","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00234-009-0544-5","article-title":"MR imaging of hypoglycemic encephalopathy: lesion distribution and prognosis prediction by diffusion-weighted imaging","volume":"51","author":"Ma","year":"2009","journal-title":"Neuroradiology"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0560","first-page":"332","article-title":"The hypothalamus\u2013pituitary\u2013thyroid axis in critical illness","volume":"67","author":"Mebis","year":"2009","journal-title":"Neth J Med"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0565","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/bmj.2.5205.1086-a","article-title":"Potassium perchlorate in thyrotoxicosis","volume":"2","author":"Morgans","year":"1960","journal-title":"Br Med J"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0570","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0580","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1042\/bj0291048","article-title":"Crystalline insulin","volume":"29","author":"Scott","year":"1935","journal-title":"Biochem J"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0585","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1172\/JCI101000","article-title":"The insulin and the zinc content of normal and diabetic pancreas","volume":"17","author":"Scott","year":"1938","journal-title":"J Clin Invest"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0590","unstructured":"Swedish Medical Products Agency quinagolide product information (2009). Sweden Medical Products Agency viewed 15OCT2013: http:\/\/www.lakemedelsverket.se\/SPC_PIL\/Pdf\/enhumspc\/Norprolac%20tablet%20ENG%20SmPC.doc"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0595","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2005.01.055","article-title":"Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway","volume":"183","author":"Ueba","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0600","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UKPDS 33","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0605","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UKPDS 34","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0610","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc090812","article-title":"Glucose control in critically ill patients","volume":"361","author":"Van den Berghe","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0615","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/ijc.20091","article-title":"Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells","volume":"109","author":"Wesley","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/B978-0-7020-4087-0.00054-1_bb0620","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1463-1326.2005.00567.x","article-title":"Novel insulin analogues and its mitogenic potential","volume":"8","author":"Zib","year":"2006","journal-title":"Diabetes Obes Metab"}],"container-title":["Handbook of Clinical Neurology","Neurologic Aspects of Systemic Disease Part II"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780702040870000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780702040870000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T21:39:31Z","timestamp":1757540371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780702040870000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9780702040870"],"references-count":123,"URL":"https:\/\/doi.org\/10.1016\/b978-0-7020-4087-0.00054-1","relation":{},"ISSN":["0072-9752"],"issn-type":[{"value":"0072-9752","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}